MRC1 and cancer: Targeting CD206 is also promising for diagnostic purposes, as an increased number of CD206+ cells in lymph nodes correlates with relapse onset in some cancers.[6] Most synthetic compounds designed to target CD206 utilize mannose as the recognition moiety.